Introduction:
LabGenius, an AI-driven antibody drug discovery company, has raised £35m in a Series B financing round. The funding will be used to expand LabGenius’ ML-driven discovery platform and progress its pipeline of multispecific antibodies towards clinical trials. LabGenius’ automated discovery engine, EVA, uses active learning methods to identify antibodies with non-intuitive designs. The company’s technology platform enables the efficient co-optimization of antibodies across multiple important properties.
- The £35m Series B financing round brings LabGenius’ total funding to £58m.
- M Ventures, Octopus Ventures, and LG Corp joined as new investors, while existing investors such as Atomico and Lux Capital also participated.
- The funding will be used to expand LabGenius’ ML-driven discovery platform and progress its pipeline of multispecific antibodies to clinical trials.
- LabGenius’ automated discovery engine, EVA, uses active learning methods to identify antibodies with non-intuitive designs.
- The technology platform allows for the efficient co-optimization of antibodies across multiple important properties.
Conclusion:
The £35m funding raised by LabGenius will enable the company to further develop its ML-driven discovery platform and advance its pipeline of multispecific antibodies. LabGenius’ technology, which includes the use of the EVA automated discovery engine, has the potential to revolutionize the field of antibody drug discovery and improve the identification of antibodies with unique characteristics. This funding round also demonstrates the confidence of investors in LabGenius’ approach and its potential to contribute to the development of new therapies.
